In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae

Yee-Huang Ku, Yin-Ching Chuang, Wen-Liang Yu
Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center, Liouying; Departments of Medical Research and Intensive Care Medicine, Chi-Mei Medical Center, Tainan; and Department of Medicine, Taipei Medical University, Taipei, Taiwan

Received: April 5, 2007    Revised: May 15, 2007    Accepted: June 25, 2007   

Dr. Wen-Liang Yu, Department of Intensive Care Medicine, Chi-Mei Medical Center, Tainan, Taiwan. E-mail: Dr. Wen-Liang Yu This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 

Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.

 

104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips.

 

The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively.

 

Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

 

beta-Lactamase resistance; beta-Lactamases; Enterobacteriaceae; Microbial sensitivity tests; Minocycline

 

J Microbiol Immunol Infect. 2008;41:332-336.